Evidence map›Paper›PMID 37145382›Full record

ReviewCurrent treatment options in oncology2023

Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?

Juan Jose Juarez-Vignon Whaley, Michelle Afkhami, Sagus Sampath, Arya Amini, Diana Bell, Victoria M Villaflor

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Integration of geriatric nutritional risk index and sarcopenia for prognostic assessment in nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: a large-scale long-term retrospective study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Juan Jose Juarez-Vignon WhaleyHealth Science Research Center, Faculty of Health Science, Universidad Anahuac Mexico, State of Mexico, Mexico City, Mexico.
Michelle AfkhamiDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Sagus SampathDepartment of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Arya AminiDepartment of Radiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Diana BellDepartment of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Victoria M VillaflorDepartment of Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA, 91010, USA. vvillaflor@coh.org.
City of Hope · USUniversidad Anáhuac · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementNasopharyngeal carcinoma (NPC) is a rare malignancy, endemic in China, that is commonly diagnosed in locally advanced scenarios. Its pathogenesis is strongly associated with Epstein-Barr virus (EBV), an infection for which measuring EBV plasma DNA levels has helped as a prognostic factor guiding treatment options, including a stronger treatment in those with high titers. Additionally, tobacco and alcohol are often implicated in EBV-negative patients. The local disease is treated with radiotherapy alone, preferentially intensity modulated radiotherapy. For locally advanced disease, the backbone treatment is concurrent chemoradiotherapy with the ongoing research dilemma being adding adjuvant chemotherapy or induction chemotherapy. The ongoing research is focused not only on identifying patients that will benefit from adjuvant or induction chemotherapy, but also on identifying the best chemotherapeutic regimen, regimen alternatives to diminish toxicity, the role that immune checkpoint inhibitors play, and the use of molecularly guided treatment targeting patients with NPC whether driven by EBV or tobacco and alcohol. Knowing the precise oncogenesis of NPC not only offers a better understanding of the role that EBV plays in this tumor but also helps create targeted therapies that could potentially block important pathways such as the NF-κB pathway. Much is yet to be done, but the prognosis and management of NPC patients have changed drastically, offering precise treatment methods and excellent control of the disease, even in locally advanced scenarios.

Indexed as

Epstein-Barr Virus InfectionsNasopharyngeal NeoplasmsChemoradiotherapyHerpesvirus 4, HumanHumansNasopharyngeal CarcinomaPrognosisAdjuvant chemotherapyConcurrent chemotherapyInduction chemotherapyLocally advanced diseaseManagement NPCNasopharyngeal carcinoma

Identifiers

PMID37145382
PMCPMC10271909
OpenAlexW4372337353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.